Quench Medical Inc.

Quench Medical Inc. is a corporate entity registered in St. Paul, Minnesota, focused on developing innovative inhaled medical technologies with a specific emphasis on pharmaceutical formulations targeting pulmonary diseases. The company specializes in creating advanced dry powder aerosol delivery platforms for therapeutic interventions, particularly in challenging medical areas such as lung cancer, opioid use disorder, and pulmonary airleaks. Their core technological approach centers on developing highly targeted inhalation-based treatments that aim to improve drug delivery efficiency, minimize systemic toxicity, and enhance patient outcomes through precise local drug administration.

The company has secured multiple federal grant awards from prominent agencies including the National Cancer Institute, National Institute on Drug Abuse, and National Heart Lung and Blood Institute, demonstrating a comprehensive research portfolio in respiratory medicine. Their grant-funded projects have focused on developing novel inhaled dry powder formulations for treating non-small cell lung cancer, exploring psychoplastogenic compounds for opioid use disorder treatment, and creating minimally invasive aerosol solutions for pulmonary airleaks. Notably, Quench Medical has engaged in collaborative research, including a sub-award partnership with Oklahoma State University to advance their digital twin testing platform for inhalation medical device innovation. Their grants, ranging from approximately $249,815 to support investigational new drug filings to developing targeted therapeutic approaches, consistently emphasize improving treatment efficacy, reducing systemic side effects, and addressing critical unmet medical needs in respiratory and oncological domains.